

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2012

Vol. 40, No. 9

CONTENTS

COMMENTARY

- Nonspecific Protein Binding versus Membrane Partitioning: It Is Not Just Semantics. *Swati Nagar and Ken Korzekwa* **1649**

SHORT COMMUNICATION

- Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions. *Yasushi Fujioka, Kent L. Kunze, and Nina Isoherranen* **1653**

ARTICLES

- Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4. *Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston, and Aleksandra Galetin* **1658**

- A Novel Ring Oxidation of 4- or 5-Substituted 2H-Oxazole to Corresponding 2-Oxazolone Catalyzed by Cytosolic Aldehyde Oxidase. *Vinod K. Arora, Thomas Philip, Stella Huang, and Yue-Zhong Shu* **1668**

- Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic. *Haiqing Wang, Lifei Wang, Kai Cao, Stuart L. Emanuel, Paul Morin, Zheng Lin, Guoxiang Shen, Jennifer Hosbach, Donglu Zhang, Samuel Bonacorsi, A. David Rodrigues, and Zheng Yang* **1677**

- Selective Mechanism-Based Inactivation of CYP3A4 by CYP3c1 (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs. *Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Held, Gregory S. Walker, Theunis C. Goosen, and Michael A. Zientek* **1686**

- Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19. *Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini*

- Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda, and A. David Rodrigues* **1698**

- Metabolism and Pharmacokinetics of Indacaterol in Humans. *Mark Kagan, Jeremy Dain, Lana Peng, and Christine Reynolds* **1712**

- Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride. *Fanying Li, Christina Chin, Julie Wangsa, and John Ho* **1723**

- Role of Human UDP-Glucuronosyltransferases in the Biotransformation of the Triazolacridinone and Imidazoacridinone Antitumor Agents C-1305 and C-1311: Highly Selective Substrates for UGT1A10. *Barbara Fedejko-Kap, Stacie M. Bratton, Moshe Finel, Anna Radomska-Pandya, and Zofia Mazerska* **1736**

- Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes. *Karelle Ménochet, Kathryn E. Kenworthy, J. Brian Houston, and Aleksandra Galetin* **1744**

- Evaluation of P450 Inhibition and Induction by Artemisinin Antimalarials in Human Liver Microsomes and Primary Human Hepatocytes. *Jie Xing, Brian J. Kirby, Dale Whittington, Yakun Wan, and David R. Goodlett* **1757**

- Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme. *Hemali T. Amunugama, Haoming Zhang, and Paul F. Hollenberg* **1765**

- Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data. *Fumihiro Nakamori, Yoichi Naritomi, Ken-ichi Hosoya, Hiroyuki Moriguchi, Kazuhiro Tetsuka, Takako Furukawa, Keitaro Kadono, Katsuhiko Yamano, Shigeyuki Terashita, and Toshio Teramura* **1771**

Continued on next page

Metabolism of the Active Metabolite of Quetiapine, *N*-Desalkylquetiapine In Vitro. *Gry Vibeke Bakken, Espen Molden, Karoline Knutsen, Niclas Lunder, and Monica Hermann* **1778**

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human. *Laurent Salphati, Jodie Pang, Emile G. Plise, Leslie B. Lee, Alan G. Olivero, Wei Wei Prior, Deepak Sampath, Susan Wong, and Xiaolin Zhang* **1785**

Evaluation of Inhibition Selectivity for Human Cytochrome P450 2A Enzymes. *Eva S. Stephens, Agnes A. Walsh, and Emily E. Scott* **1797**

Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5. *Xiaohai Li, Xinyi Song, Theodore M. Kamenecka, and Michael D. Cameron* **1803**

Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent. *Jan Scicinski, Bryan Oronsky, Michael Taylor, Gang Luo, Timothy Musick, Joseph Marini, Christopher M. Adams, and William L. Fitch* **1810**

Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease. *Mark J. Canet, Rhannon N. Hardwick, April D. Lake, Michael J. Kopplin, George L. Scheffer, Walter T. Klimecki, A. Jay Gandolfi, and Nathan J. Cherrington* **1817**

Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics. *Maciej J. Zamek-Gliszczynski, David W. Bedwell, Jing Q. Bao, and J. William Higgins* **1825**

The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5. *Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, Tammy S. Santomango, Thomas M. Bridges, Donald Stec, Katrina A. Brewer, Raymundo Sanchez-Ponce, Melany M. Corlew, Roger Rush, Andrew S. Felts, Jason Manka, Brittney S. Bates, Daryl F. Venable, Alice L. Rodriguez, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, and J. Scott Daniels* **1834**

Influence of Enterohepatic Recycling on the Time Course of Brain-to-Blood Partitioning of Valproic Acid in Rats. *Jeannie M. Padowski and Gary M. Pollack* **1846**

Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate. *Katsunobu Hagihara, Miho Kazui, Atsushi Kurihara, Toshiko Ikeda, and Takashi Izumi* **1854**

ACCELERATED COMMUNICATION

A Novel Relay Method for Determining Low-Clearance Values. *Li Di, Patrick Trapa, R. Scott Obach, Karen Atkinson, Yi-An Bi, Angela C. Wolford, Beijing Tan, Thomas S. McDonald, Yurong Lai, and Larry M. Tremaine* **1860**

ERRATA

Correction to “Identification of Novel Metoclopramide Metabolites in Human: In Vitro and In Vivo Studies” **1866**

Correction to “Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drug via Ligand-Based Virtual Screening” **1868**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Schematic representation of a 40-kDa branched PEGylated Adnectin (P40BEI-tandem). See the article by Wang et al. on page 1677 of this issue.